NH125, an eukaryotic elongation factor 2 kinase inhibitor, radiosensitizes breast cancer by the abrogation of G2/M checkpoint

Abstract Radiotherapy remains an important treatment option for both surgical and non-surgical breast cancer patients; however resistance to radiation results in tumor recurrence and metastasis. eEF2K has been reported to play a